Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Two drugs added to the Most Cost-Effective Setting Program

September 15, 2021

Effective September 15, 2021, the following specialty medical benefit drugs were added to our Most Cost-Effective Setting Program:

  • Nexviazyme™ (avalglucosidase-alfa-ngpt) 
  • Saphnelo™ (anifrolumab-fnia)

New requests for these drugs will require review for setting, as well as medical necessity, during the precertification process. Members who have precertification approval to receive these drugs in a hospital outpatient facility may continue treatment in this setting until their current precertification approval expires. At the next precertification review, Independence will evaluate the requested setting and make a coverage determination.

Independence seeks to ensure that our members receive injectable/infusion therapy drugs in a setting that is both safe and cost-effective. We continually review the most appropriate setting for commercial members to receive selected injectable and infusion therapy drugs eligible for coverage under the medical benefit.

Resources

For more information, including a downloadable list of all 78 drugs in the program, visit our Most Cost-Effective Setting Program webpages:


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.